Key facts
- It has raised $27.3M across 1 recorded rounds; the latest was Early Stage VC ($12.3M) in May 2024.
- Notable investors include Bantam Group, 2ndF, Genoa Ventures, Anzu Partners, VC23 Investors.
- Codetta Bio has filed 2 Form Ds with the SEC, most recently Oct 2024 ($12.3M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Codetta Bio
Funding rounds
1 roundsAbout Codetta Bio
Developer of multi-omic analysis tools designed for comprehensive biomarker measurement. The company combines digital PCR, real-time PCR, and immunoPCR technologies to analyze proteins, DNA, and RNA from a single sample, enabling research and clinical markets to obtain integrated biomarker data from one specimen.
- Sector
- Healthcare
- HQ
- Morrisville, NC, United States
- Founded
- 2021
- Employees
- 36
- Website
- codettabio.com/
- Ownership
- Privately Held (backing)
Codetta Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Codetta Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Codetta Bio in its N-PORT filings yet. We sweep new filings monthly.